Baxter (NYSE:BAX) today released data from multiple studies of its Sharesource remote patient monitoring technology used for peritoneal dialysis patient care.
Data from the study was presented at the 54th Congress of the European Renal Association and European Dialysis and Transplant Association meeting this week.
Sharesource is a 2-way cloud-based technology offered with the company’s Homechoice Claria automated PD system to allow providers to connect with patients using the device and verify patient adherence, the company said.
Data from the 1st study study, which included 399 APD patients using remote patient management for over a 1-year, indicated an average of 30% of patients were non-adherent during their 1st months of therapy. The company said that the Sharesource platform provided more accurate and timely visibility of adherence issues, allowing for earlier interventions.
Data from a 2nd study showed that remote patient management was associated changes in PD nursing habits, providing nurses with more proactive clinical management time and better patient prioritization, as well as up to a 35% increase in time available to perform proactive patient related tasks.
Preliminary results on early PD attrition from the PDOPPS Baxter-cosponsored study indicated that approximately 10% of PD patients drop out within 120 days to move to hemodialysis, with catheter-related complications being the most frequent reason for the transfer. The company said that further patient recruitment would aid in understanding causes and developing recommendations for improving patient stay length.
“Baxter’s Sharesource remote patient management system was designed to support patients’ access to PD, with the confidence to perform home therapy knowing their healthcare providers are remotely managing their care. New data show the technology can help healthcare providers achieve this goal because they have timely access to accurate patient therapy adherence data, allowing them to address pertinent clinical issues earlier,” senior medical director Dr. James Sloand said in a press release.
Yesterday, Baxter released data from 2 independent studies of its novel HDx therapy using the Theranova dialyzer, touting the effective removal of small and mid-sized toxins at similar rates compared to hemodiafiltration.
